The North America Metastatic Cancer Drugs Market would witness market growth of 6.7% CAGR during the forecast period (2023-2030).
Metastatic cancer is treated with greater difficulty than early-stage cancer. Although most treatments focus on providing palliative care, metastatic cancer is treatable in some circumstances. The expenditure of R&D in the field of oncology has increased along with the frequency of disease and the length of life. In addition, several biopharmaceutical companies are attempting to enter the market and investing in the oncology field to satisfy the growing treatment needs of patients with metastatic cancer. These companies continue to pursue cost-effective oncology drugs with a high output level. Additionally, the emergence of precision medicine in the healthcare sector presents a chance for creating customized cancer treatments.
Lung, breast, prostate, and colorectal cancer are the four most common kinds of cancer. Additionally, the biopharmaceutical sector has experienced tremendous growth, which has led to the creation of several new, cutting-edge medications that can effectively target cancer cells while causing no harm to healthy cells. The market is expanding rapidly due to the growing public awareness of the availability of numerous cutting-edge treatments to treat cancer.
As per National Cancer Institute, the number of new cancer cases expected to be diagnosed in the US in 2020 is 1,806,590, while the number of cancer-related deaths is predicted to be 606,520. In 2020, it is anticipated that 43% of all cancer diagnoses in men will be prostate, lung, and colorectal. Breast, lung, and colorectal cancers are the three most prevalent cancers in women, and in 2020, new cancer diagnoses in women are expected to account for 50% of all new cancer diagnoses. Men are more likely than women to die from cancer (189.5 per 100,000 men and 135.7 per 100,000 women).
There were reportedly 16.9 million cancer survivors in the United States as of January 2019. By 2030, the number of cancer survivors is expected to reach 22,2 million. One thousand seven hundred thirty cancer-related deaths and 16,850 new cancer diagnoses are expected in children and teenagers aged 0 to 19 in 2020. In Canada, 233,900 new instances of cancer and 85 100 cancer-related deaths are anticipated in 2022. As a result of the rising cases of cancer across the region, the market is estimated to grow at a steady pace.
The US market dominated the North America Metastatic Cancer Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $36,469.5 million by 2030. The Canada market is experiencing a CAGR of 9.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Indication, the market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma & Others. Based on Therapy, the market is segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Metastatic Cancer Drugs Market is Projected to reach USD 115.6 Billion by 2030, at a CAGR of 7.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.
By Distribution Channel
By Indication
By Therapy
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
